{"id":"single-dose-liposomal-bupivicaine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, edema)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Systemic toxicity (rare at recommended doses)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bupivacaine blocks sodium channels in nerve cell membranes to prevent action potential propagation and pain signal transmission. By encapsulating bupivacaine in liposomal vesicles, the formulation extends drug release over 72 hours or longer, providing sustained local anesthesia and analgesia compared to conventional bupivacaine solutions. This allows for single-dose administration with extended pain relief in surgical and regional anesthesia settings.","oneSentence":"Liposomal bupivacaine is a local anesthetic encapsulated in liposomes that provides prolonged nerve blockade by slowly releasing bupivacaine at the injection site.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:39.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Infiltration anesthesia and nerve block for surgical anesthesia and postoperative analgesia"}]},"trialDetails":[{"nctId":"NCT03737604","phase":"PHASE4","title":"TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2018-10-04","conditions":"Transplant;Failure,Kidney, Pain, Postoperative","enrollment":200},{"nctId":"NCT04603911","phase":"PHASE2","title":"RCT Comparing ESPB Solutions in Breast Surgery","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2020-12-04","conditions":"Breast Cancer","enrollment":75},{"nctId":"NCT03303794","phase":"PHASE3","title":"0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2017-10-25","conditions":"Anesthesia","enrollment":25},{"nctId":"NCT02178553","phase":"PHASE4","title":"Study of Exparel Versus Epidural for Pain Control After Thoracotomy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-10-15","conditions":"Pain Following Thoracotomy Surgery","enrollment":102},{"nctId":"NCT02390440","phase":"PHASE4","title":"Exparel for Pain Control During Care of Rib Fractures","status":"WITHDRAWN","sponsor":"Michael Moncure, MD","startDate":"2015-04","conditions":"Pain","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TAP block with liposomal bupivacaine"],"phase":"marketed","status":"active","brandName":"Single Dose Liposomal Bupivicaine","genericName":"Single Dose Liposomal Bupivicaine","companyName":"University of California, Davis","companyId":"university-of-california-davis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Liposomal bupivacaine is a local anesthetic encapsulated in liposomes that provides prolonged nerve blockade by slowly releasing bupivacaine at the injection site. Used for Infiltration anesthesia and nerve block for surgical anesthesia and postoperative analgesia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}